|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
In this study, we explored the effect of combined use of dabrafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, on BRAF(V600E)-mutant CRC stem cells and its possible mechanisms.
|
29534162 |
2018 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of hereditary non-polyposis colorectal cancer (Lynch's syndrome) and for the prediction of sensitivity to MEK inhibitors.
|
18428050 |
2008 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
No point mutation was detected in BRAF codon Val600Glu for the studied CRC patients.
|
23297805 |
2013 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The MSS/BRAF(V600E) subtype was associated with increased disease-specific mortality even in stage I-II CRC.
|
25973534 |
2015 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We demonstrate that SSA-associated synchronous colorectal carcinomas have a striking predilection for elderly women, are associated with a favorable prognosis, and are MSI-H and BRAF V600E positive.
|
23887157 |
2013 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
The absence of BRAF V600E mutation separates LLS colorectal carcinomas from MLH1-methylated colorectal carcinomas with CIMP-positive phenotype.
|
30575961 |
2019 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
We show MCC expression is dramatically decreased in many CRC cell lines and the distinct subset of sporadic CRC characterized by the CpG island methylator phenotype and BRAF(V600E) mutation due to promoter methylation as reported previously.
|
18591935 |
2008 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
|
17060676 |
2006 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia.
|
25862899 |
2015 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
|
23012255 |
2012 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Further preclinical and clinical investigations are needed to clarify the role of non-V600E mutations in CRC.
|
30463788 |
2018 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Clinicopathological and molecular features can identify CRC patients with a higher prevalence of BRAF(V600E).
|
20635392 |
2011 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
There were also tendencies toward associations of Fn-high with the BRAF V600E mutation (P = 0.047) and active Crohn-like lymphoid reactions (P = 0.052) in MSI-H CRCs.
|
28597080 |
2017 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Indeed, whereas the median overall survival (OS) of colorectal cancer (CRC) patients receiving standard-of-care therapy is approximately two years or more if their tumors express wild-type BRAF and wild-type KRAS, median OS is less than twelve months with tumors expressing V600E-mutant BRAF and wild-type KRAS.
|
23792567 |
2013 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
None of the MMRD small bowel adenocarcinomas harbored the BRAF V600E mutation, whereas 60% of MMRD colorectal carcinomas were positive for BRAF V600E with concurrent loss of MLH1 and PMS2 expression.
|
27258561 |
2017 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Real-time polymerase chain reaction identifies the most common BRAF mutation, V600E, in frozen or paraffin-embedded colorectal cancer tissue.
|
20670148 |
2010 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
These results seem to indicate that Cdx2 may play a role in the serrated pathway to colorectal cancer as underlined by strong relationships with BRAF(V600E), CIMP-high and MMR-deficiency.
|
24166180 |
2014 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
UNIPROT |
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
|
23429431 |
2013 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Because vemurafenib has shown limited single-agent clinical activity in BRAF(V600E)-mutant metastatic CRC, we therefore explored a range of combination therapies, with both standard agents and targeted inhibitors in preclinical xenograft models.
|
22180495 |
2012 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
IHC is a suitable method to screen BRAF V600E mutation in FFPE samples of CRCs and PTCs.
|
30009773 |
2018 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Overall, IHC with anti-BRAF V600E (VE1) antibody using recommended protocol with OptiView detection is optimal for detection of BRAF V600E mutation in CRC.
|
29127628 |
2019 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Thus, VE1 immunohistochemistry is a highly sensitive and specific method in detecting BRAF (V600E) mutations in colorectal carcinoma.
|
24085553 |
2013 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Double-hit therapies aimed at simultaneous inhibition of epidermal growth factor receptor and BRAF warrant exploration in CR</span>C patients carrying the V600E oncogenic mutation.
|
19001320 |
2008 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Moreover, proliferation and invasion assays were conducted using cell lines. miRNA array analysis revealed that microRNA-31 (miR-31)-5p was the most up-regulated miRNA in CRCs with mutated BRAF (V600E) compared with CRCs possessing wild-type BRAF (including cases with KRAS mutation).
|
24242331 |
2014 |
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Here, we investigate molecular responses upon single and multi-target treatments, over time, using BRAF(V600E) mutant colorectal cancer cells as a model system.
|
29970458 |
2018 |